Femasys (FEMY) AI Stock Analysis

• Market Cap: $23.13M
• Dividend Yield: N/A
• Average Volume (3M): 216.38K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.70
• Revenue Growth: 98.61%
• EPS Growth: -1.98%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.16
• Shares Outstanding: 32,575,405
• 10 Day Avg. Volume: 328,292
• 30 Day Avg. Volume: 216,376
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.41
• Enterprise Value/Revenue: 17.24
• Enterprise Value/Gross Profit: 32.10
• Enterprise Value/Ebitda: -1.77
• 1Y Price Target: $4.00
• Price Target Upside: 463.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 43 Neutral
• Price Target: $1.00 ▲(40.85% Upside)

Femasys faces significant financial and operational challenges, reflected in its low financial performance and valuation scores. While recent corporate events show strategic progress, they are overshadowed by financial instability and compliance issues. The technical analysis indicates a bearish trend, further impacting the overall score.

Positive Factors

International Expansion

Femasys announced a $400k order of FemBloc in Spain, marking the start of international sales and EU expansion.

Leadership and Growth Strategy

The appointment of Kelly Nicholas as Chief Commercial Officer is expected to help drive sales growth due to her extensive experience in commercializing medical devices.

Regulatory Approvals

FemaSeed obtained FDA 510(k) clearance, offering a novel and unique form of artificial insemination that could increase pregnancy success rates.

Negative Factors

Regulatory and Market Risks

Risks include safety signals, lower-than-expected efficacy, commercial competition, regulatory concerns, and financing requirements.

Revenue Performance

2Q25 revenues lower than estimated; though room for growth is on the horizon.

Sales and Revenue Challenges

The sales ramp is slower than anticipated, leading to a lower 2025 revenue estimate.

Femasys Business Overview & Revenue Model

Company Description

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

How the Company Makes Money

Femasys makes money primarily through the development and commercialization of its medical devices and technologies. The company's revenue streams are mainly derived from the sale of its proprietary products, such as FemBloc, a non-surgical permanent birth control solution, and FemVue, an infertility diagnosis product. Femasys may also engage in strategic partnerships and licensing agreements with healthcare providers and distributors to expand the reach of its products, contributing to its revenue. The company's earnings are influenced by the demand for its innovative solutions in women's health and its ability to successfully navigate regulatory approvals and market competition.

Femasys Financial Statement Overview

Summary

Femasys is facing significant financial challenges, with persistent losses and negative cash flows. Despite some revenue growth, the company struggles with operational inefficiencies and financial instability, requiring urgent improvements in financial health and profitability.

Income Statement

Femasys has shown a slight increase in revenue over the years, but the company remains unprofitable with consistent negative EBIT and EBITDA margins. The net profit margin remains negative, and the revenue growth rate is volatile, suggesting challenges in achieving stable growth.

Balance Sheet

The balance sheet reflects financial instability with a negative equity position in earlier years, improving to positive but weak equity levels recently. The debt-to-equity ratio indicates high leverage, which could pose risks if not managed carefully. The company needs to strengthen its equity base for financial stability.

Cash Flow

Femasys consistently experiences negative operating and free cash flows, indicating operational challenges and a reliance on external financing. The cash flow to net income ratios are unfavorable, emphasizing the company's struggle to generate cash through operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.89M	1.63M	1.07M	1.21M	1.18M	1.04M
Gross Profit	1.01M	1.08M	691.90K	764.28K	809.30K	731.38K
EBITDA	-18.34M	-16.33M	-13.17M	-10.49M	-6.55M	-5.80M
Net Income	-21.02M	-18.82M	-14.25M	-11.39M	-7.54M	-6.91M
Balance Sheet
Total Assets	2.43M	12.45M	27.76M	16.90M	28.58M	7.61M
Cash, Cash Equivalents and Short-Term Investments	3.22M	3.45M	21.72M	12.96M	24.78M	3.32M
Total Debt	7.85M	7.44M	6.70M	543.72K	990.21K	2.06M
Total Liabilities	12.27M	10.14M	9.40M	1.65M	2.24M	59.42M
Stockholders Equity	1.51M	2.30M	18.35M	15.24M	26.33M	-51.82M
Cash Flow
Free Cash Flow	-20.41M	-20.21M	-11.42M	-11.14M	-8.24M	-4.96M
Operating Cash Flow	-19.67M	-19.44M	-11.28M	-10.73M	-7.93M	-4.93M
Investing Cash Flow	-744.21K	-847.76K	-143.92K	-407.48K	-306.87K	968.32K
Financing Cash Flow	10.10M	2.03M	20.18M	-681.64K	29.70M	871.65K

Femasys Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 0.71 is below the 20-day moving average (MA) of 0.83, below the 50-day MA of 0.88, and below the 200-day MA of 1.12, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 34.37 is Neutral, neither overbought nor oversold. The STOCH value of 3.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.

Femasys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	67 Neutral	$12.23M	1.11	7.10%	―	-0.19%	-18.41%
Sector *	65 Neutral	¥343.60B	11.39	-0.17%	2.39%	9.60%	-12.34%
HBIO	55 Neutral	$23.56M	―	-138.36%	―	-12.24%	-427.45%
RVP	52 Neutral	$23.81M	―	-10.80%	―	-0.24%	50.45%
MLSS	47 Neutral	$51.06M	―	-123.50%	―	7.84%	-43.00%
FEMY	43 Neutral	$23.13M	―	-329.45%	―	98.61%	-1.98%
POAI	39 Underperform	$9.33M	―	-708.73%	―	-38.79%	58.27%

Femasys Corporate Events

Femasys Enters European Market with Major Spain Order

On August 6, 2025, Femasys Inc. announced its first commercial entry into Europe with a $400,000 order for FemBloc Permanent Birth Control in Spain, marking a strategic milestone in its global expansion. FemBloc, a revolutionary non-surgical permanent contraceptive, offers a less invasive and cost-effective alternative to traditional methods, and its introduction in Spain is supported by partnerships with Comercial Medico Quirúrgica and Durgalab. This development is expected to enhance Femasys’s market positioning and meet growing demand across Europe.

Femasys Faces Nasdaq Noncompliance Notice for Stock Price

On July 16, 2025, Femasys Inc. received a notice from Nasdaq indicating noncompliance with the Minimum Bid Price Requirement, as the company’s stock price had been below $1.00 for 30 consecutive business days. This notification does not immediately affect the trading of Femasys’ stock, but the company has until January 12, 2026, to meet the requirement. Femasys may consider options such as a reverse stock split to regain compliance, but there is no assurance of success.

Femasys Enters Purchase Agreement with Alumni Capital

On June 30, 2025, Femasys Inc. entered into a Purchase Agreement with Alumni Capital LP, allowing the company to sell up to $10 million of its common stock over a specified period. This agreement provides Femasys with flexibility in financing, contingent on market conditions and trading prices, while ensuring compliance with regulatory requirements and ownership limitations.

Femasys Gains Regulatory Approvals in Australia and New Zealand

On July 1, 2025, Femasys Inc. announced the achievement of regulatory approvals in Australia and New Zealand for its infertility solutions, FemaSeed for first-line intratubal insemination treatment and FemVue for diagnostic evaluation. These approvals mark a significant milestone in expanding global access to Femasys’ innovative infertility solutions, validating the clinical value of their platform and creating meaningful commercial opportunities. This development reinforces Femasys’ commitment to providing accessible, first-line infertility solutions, addressing critical gaps in care for women struggling with infertility.

Femasys Approves Director Elections and Share Increase

On June 25, 2025, Femasys Inc. held its Annual Meeting of Stockholders, where approximately 59.41% of the total outstanding shares were represented. During the meeting, stockholders approved the election of two Class I directors, an amendment to the 2021 Equity Incentive Plan to increase authorized shares by 3,000,000, and ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025.

Femasys Gains European Approval for FemBloc System

On June 25, 2025, Femasys Inc. announced the European CE mark approval of FemBloc, the first non-surgical permanent birth control system. This approval marks a significant milestone for the company, allowing the FemBloc system to be marketed across the European Economic Area. The FemBloc system, which offers a safer and more cost-effective alternative to traditional surgical sterilization, is set to be commercially available in Spain and other select European countries. This development underscores Femasys’ commitment to providing innovative solutions in women’s health and is expected to enhance its industry positioning and impact stakeholders positively.

Femasys Appoints Kelley Nicholas as Chief Commercial Officer

On June 17, 2025, Femasys Inc. announced the appointment of Kelley Nicholas as Chief Commercial Officer to lead the U.S. commercialization of fertility products and expand global partnerships. Ms. Nicholas, with over 25 years of industry experience, is expected to drive revenue growth and strengthen Femasys’ position in women’s health. The company also granted her an option to purchase 100,000 shares of common stock as an inducement for her employment.

Femasys Announces Public Offering and Private Placement

On May 29, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC for a public offering of 3,600,000 shares of common stock at $0.85 per share. The company also initiated a concurrent private placement with existing institutional stockholders and certain directors and officers, raising a total of approximately $4.5 million before expenses. The proceeds are intended for commercial expansion, product development, and general corporate purposes. Additionally, Femasys agreed to establish a $10 million equity line of credit with Alumni Capital LP by June 30, 2025, with potential penalties if not completed.

Femasys Receives Nasdaq Delisting Notice for Low Market Value

On May 19, 2025, Femasys received a notice from Nasdaq indicating that the market value of its listed securities had fallen below the required $35 million for continued listing on the Nasdaq Capital Market. The company has until November 17, 2025, to regain compliance, or it may face delisting. Femasys plans to actively monitor its market value and explore options to meet the requirement, although there is no assurance of success.